2023 article

A second-generation, point-of-care immunoassay provided improved detection of Anaplasma and Ehrlichia antibodies in PCR-positive dogs naturally infected with Anaplasma or Ehrlichia species

Richardson, S. S., Mainville, C. A., Arguello-Marin, A., Whalley, D., Burton, W., Breitschwerdt, E. B., & Qurollo, B. A. (2023, May 9). JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION.

By: S. Richardson n, C. Mainville*, A. Arguello-Marin*, D. Whalley*, W. Burton*, E. Breitschwerdt n, B. Qurollo n

co-author countries: United States of America 🇺🇸
author keywords: Anaplasma; dogs; Ehrlichia; immunoassay; point-of-care; serology; tick-borne pathogens
Source: Web Of Science
Added: May 30, 2023

A validated second-generation SNAP 4Dx Plus (Idexx) incorporates new peptides for improved detection of antibodies against Anaplasma and Ehrlichia tick-borne pathogens in dogs. We compared the first- and second-generation SNAP 4Dx Plus using dogs naturally infected with Anaplasma or Ehrlichia species, or dogs seroreactive by an E. canis indirect fluorescent antibody test (IFAT). The second-generation immunoassay was more sensitive than the first-generation for dogs infected with A. phagocytophilum (51.1% and 29.2%, respectively), A. platys (63.6% and 35.3%, respectively), E. canis (96.2% and 88.3%, respectively), or E. ewingii (73.7% and 70.8%, respectively), and for dogs seroreactive by E. canis IFAT (87.3% and 83.9%, respectively). The second-generation immunoassay detected significantly more Anaplasma- or Ehrlichia-infected dogs that were Anaplasma ( p < 0.001) or Ehrlichia ( p = 0.031) seroreactive, respectively, than did the first-generation test. When Ehrlichia seroreactivity by E. canis IFAT and both immunoassays was compared, significantly more E. canis–infected dogs were seroreactive by E. canis IFAT than the first-generation ( p = 0.006) but not the second-generation ( p = 0.125) immunoassay. Significantly more E. ewingii–infected dogs were seroreactive by the first- ( p = 0.011) and second-generation ( p = 0.049) immunoassays than the E. canis IFAT. Medical records available for 7 dogs that were Anaplasma seroreactive by the second-generation but not the first-generation immunoassay revealed case management decisions that might have been different with an immediate anaplasmosis diagnosis, including earlier doxycycline therapy and less hospitalization. The second-generation SNAP 4Dx Plus test offered improved serologic detection of Anaplasma and Ehrlichia in naturally infected dogs.